The abstract is read at the publisher; the summary is JClub's.
MOG-directed human CD4+ CAR T cells reproducibly generate perivascular demyelinating lesions in mouse optic nerves, enabling remyelination testing within persistently inflamed foci.
- Why it matters: Existing multiple sclerosis therapies mainly dampen inflammation, while remyelination failure in persistently inflamed lesions limits progress.
- What they did: Human CD4+ CAR T cells targeting MOG were transferred into immunodeficient mice to infiltrate CNS tissues and form discrete optic nerve lesions; clemastine was then administered.
- The result: Clemastine reduced optic nerve lesion size and improved optic nerve conduction despite persistent inflammation, supporting this model for evaluating remyelinating therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.